vs

Side-by-side financial comparison of Churchill Downs Inc (CHDN) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Churchill Downs Inc is the larger business by last-quarter revenue ($663.0M vs $622.0M, roughly 1.1× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 12.5%, a 21.9% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 3.1%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -13.7%).

Churchill Downs Incorporated is the parent company of Churchill Downs. The company has evolved from one racetrack in Louisville, Kentucky, to a multi American-state-wide, publicly traded company with racetracks, casinos and an online wagering company among its portfolio of businesses.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

CHDN vs RPRX — Head-to-Head

Bigger by revenue
CHDN
CHDN
1.1× larger
CHDN
$663.0M
$622.0M
RPRX
Growing faster (revenue YoY)
RPRX
RPRX
+1.7% gap
RPRX
4.8%
3.1%
CHDN
Higher net margin
RPRX
RPRX
21.9% more per $
RPRX
34.4%
12.5%
CHDN
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
-13.7%
CHDN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CHDN
CHDN
RPRX
RPRX
Revenue
$663.0M
$622.0M
Net Profit
$83.0M
$214.2M
Gross Margin
Operating Margin
21.6%
62.4%
Net Margin
12.5%
34.4%
Revenue YoY
3.1%
4.8%
Net Profit YoY
7.8%
2.9%
EPS (diluted)
$1.16
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHDN
CHDN
RPRX
RPRX
Q1 26
$663.0M
Q4 25
$665.9M
$622.0M
Q3 25
$683.0M
$609.3M
Q2 25
$934.4M
$578.7M
Q1 25
$642.6M
$568.2M
Q4 24
$624.2M
$593.6M
Q3 24
$628.5M
$564.7M
Q2 24
$890.7M
$537.3M
Net Profit
CHDN
CHDN
RPRX
RPRX
Q1 26
$83.0M
Q4 25
$51.3M
$214.2M
Q3 25
$38.1M
$288.2M
Q2 25
$216.9M
$30.2M
Q1 25
$76.7M
$238.3M
Q4 24
$71.7M
$208.2M
Q3 24
$65.4M
$544.0M
Q2 24
$209.3M
$102.0M
Operating Margin
CHDN
CHDN
RPRX
RPRX
Q1 26
21.6%
Q4 25
18.5%
62.4%
Q3 25
14.3%
70.1%
Q2 25
35.1%
36.3%
Q1 25
20.9%
94.0%
Q4 24
20.3%
60.9%
Q3 24
20.0%
Q2 24
37.0%
50.2%
Net Margin
CHDN
CHDN
RPRX
RPRX
Q1 26
12.5%
Q4 25
7.7%
34.4%
Q3 25
5.6%
47.3%
Q2 25
23.2%
5.2%
Q1 25
11.9%
41.9%
Q4 24
11.5%
35.1%
Q3 24
10.4%
96.3%
Q2 24
23.5%
19.0%
EPS (diluted)
CHDN
CHDN
RPRX
RPRX
Q1 26
$1.16
Q4 25
$0.49
Q3 25
$0.67
Q2 25
$0.07
Q1 25
$0.55
Q4 24
$0.46
Q3 24
$1.21
Q2 24
$0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHDN
CHDN
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$200.0M
$618.7M
Total DebtLower is stronger
$840.0M
$9.0B
Stockholders' EquityBook value
$9.7B
Total Assets
$7.5B
$19.6B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHDN
CHDN
RPRX
RPRX
Q1 26
$200.0M
Q4 25
$200.6M
$618.7M
Q3 25
$180.5M
$938.9M
Q2 25
$182.4M
$631.9M
Q1 25
$174.2M
$1.1B
Q4 24
$175.5M
$929.0M
Q3 24
$152.7M
$950.1M
Q2 24
$140.3M
$1.8B
Total Debt
CHDN
CHDN
RPRX
RPRX
Q1 26
$840.0M
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Stockholders' Equity
CHDN
CHDN
RPRX
RPRX
Q1 26
Q4 25
$1.0B
$9.7B
Q3 25
$1.0B
$9.6B
Q2 25
$1.0B
$9.5B
Q1 25
$1.1B
$9.8B
Q4 24
$1.1B
$10.3B
Q3 24
$1.1B
$10.3B
Q2 24
$1.0B
$9.8B
Total Assets
CHDN
CHDN
RPRX
RPRX
Q1 26
$7.5B
Q4 25
$7.5B
$19.6B
Q3 25
$7.5B
$19.3B
Q2 25
$7.4B
$18.3B
Q1 25
$7.3B
$17.6B
Q4 24
$7.3B
$18.2B
Q3 24
$7.2B
$18.0B
Q2 24
$7.2B
$17.7B
Debt / Equity
CHDN
CHDN
RPRX
RPRX
Q1 26
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHDN
CHDN
RPRX
RPRX
Operating Cash FlowLast quarter
$295.0M
$827.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
3.55×
3.86×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHDN
CHDN
RPRX
RPRX
Q1 26
$295.0M
Q4 25
$827.1M
Q3 25
$187.7M
$702.6M
Q2 25
$364.0M
Q1 25
$246.5M
$596.1M
Q4 24
$742.5M
Q3 24
$169.4M
$703.6M
Q2 24
$658.2M
Free Cash Flow
CHDN
CHDN
RPRX
RPRX
Q1 26
Q4 25
Q3 25
$166.3M
Q2 25
Q1 25
$233.9M
Q4 24
Q3 24
$154.4M
Q2 24
FCF Margin
CHDN
CHDN
RPRX
RPRX
Q1 26
Q4 25
Q3 25
24.3%
Q2 25
Q1 25
36.4%
Q4 24
Q3 24
24.6%
Q2 24
Capex Intensity
CHDN
CHDN
RPRX
RPRX
Q1 26
Q4 25
2.6%
Q3 25
3.1%
Q2 25
2.0%
Q1 25
2.0%
Q4 24
5.4%
Q3 24
2.4%
Q2 24
2.5%
Cash Conversion
CHDN
CHDN
RPRX
RPRX
Q1 26
3.55×
Q4 25
3.86×
Q3 25
4.93×
2.44×
Q2 25
12.06×
Q1 25
3.21×
2.50×
Q4 24
3.57×
Q3 24
2.59×
1.29×
Q2 24
6.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHDN
CHDN

Live and Historical Racing$297.0M45%
Gaming$257.0M39%
Wagering Services and Solutions$109.0M16%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons